Oral glucose ingestion stimulates cholecystokinin release in normal subjects and patients with non-insulin-dependent diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 45, Issue 2, 1996, Pages 196-202

  Hasegawa, Hiroshi ^b   Shirohara, Hisashi ^b   Okabayashi, Yoshinori ^b   Nakamura, Takahiko ^b   Fujii, Masatoshi ^b   Koide, Makoto ^b   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; GLUCOSE; INSULIN;

ADULT; ARTICLE; CHOLECYSTOKININ BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTAKE; GLUCOSE TRANSPORT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0030007475     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90053-0     Document Type: Article

References (47)

1. Elrick H, Stimmler L, Hlad CJ Jr, et al: Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24:1076-1082, 1964
2. McIntyre N, Holdsworth CD, Turner DS: New interpretation of oral glucose tolerance. Lancet 2:20-21, 1964
3. Unger RH, Eisentraut AH: Entero-insular axis. Arch Intern Med 123:261-266, 1969
4. Creutzfeldt W, Ebert R: New development in the incretin concept. Diabetologia 28:565-573, 1985
5. Nauck M, Schmidt WE, Ebert R, et al: Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 69:654-662, 1989
6. Ahren B, Pettersson M, Uvnas-Moberg K, et al: Effect of cholecystpkinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man. Diabetes Res Clin Pract 13:153-162, 1991
7. Okabayashi Y, Otsuki M, Baba S: Cholecystokinin in the entero-insular axis. Diabetes Res Clin Pract 7:S79-S85, 1989
8. Rushakoff RJ, Liddle RA, Williams JA, et al: The role of cholecystokinin and other gut peptides on regulation of postprandial glucose and insulin levels, in Cuatrecasas P, Jacobs S (eds): Insulin. Handbook of Experimental Pharmacology, vol 92. Berlin, Germany, Springer Verlag, 1990, pp 125-142
9. Liddle RA, Goldfine ID, Rosen MS, et al: Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75:1144-1152, 1985
10. Liddle RA, Rushakoff RJ, Morita ET, et al: Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J Clin Invest 81:1675-1681, 1988
11. Koide M, Okabayashi Y, Otsuki M: Role of endogenous bile on basal and postprandial CCK release in humans. Dig Dis Sci 38:1289-1290, 1993
12. Liddle RA, Morita ET, Conrad CK, et al: Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 77:992-996, 1986
13. Meyer BM, Werth BA, Beglinger C, et al: Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet 2:12-15, 1989
14. Hildebrand P, Beglinger C, Gyr K, et al: Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man. J Clin Invest 85:640-646, 1990
15. Schmidt WE, Creutzfeldt W, Schleser A, et al: Role of CCK in regulation of pancreaticobiliary function and GI motility in humans: Effects of loxiglumide. Am J Physiol 260:G197-G206, 1991
16. Otsuki M, Sakamoto C, Yuu H, et al: Discrepancies between the doses of cholecystokinin or caerulein-stimulating exocrine and endocrine responses in perfused isolated rat pancreas. J Clin Invest 63:478-484, 1979
17. Hermansen K: Effects of cholecystokinin (CCK)-4, nonsulfated CCK-8, and sulfated CCK-8 on pancreatic somatostatin, insulin, and glucagon secretion in the dog: Studies in vitro. Endocrinology 114:1770-1775, 1984
18. Verspohl EJ, Ammon HPT, Williams JA, et al: Evidence that cholecystokinin interacts with specific receptors and regulates insulin release in isolated rat islets of Langerhans. Diabetes 35:38-43, 1986
19. Rossetti L, Shulman GI, Zawalich WS: Physiological role of cholecystokinin in meal-induced insulin secretion in conscious rats. Studies with L364718, a specific inhibitor of CCK-receptor binding. Diabetes 36:1212-1215, 1987
20. Sakamoto C, Goldfine ID, Roach E, et al: Localization of saturable CCK binding sites in rat pancreatic islet by light and electron microscopic autoradiography. Diabetes 34:390-394, 1985
21. Okabayashi Y, Otsuki M, Nakamura T, et al: Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas. Pancreas 5:291-297, 1990
22. Karlsson S, Ahren B: CCK-8-stimulated insulin secretion in vivo is mediated by CCKA receptors. Eur J Pharmacol 213:145-146, 1992
23. Otsuki M, Okabayashi Y, Nakamura T, et al: Bioassay of plasma cholecystokinin in rat and human: Inhibition of protein synthesis prevents the decrease in the sensitivity and responsiveness of isolated rat pancreatic acini to CCK-8. Pancreas 4:447-451, 1989
24. Tachibana I, Watanabe N, Shirohara H, et al: Effects of tetraprenylacetone on pancreatic exocrine secretion and acute pancreatitis in two experimental models in rats. Int J Pancreatol 17:147-154, 1995
25. 14C-labelled HB 419. Horm Metab Res 1:51-54, 1969 (suppl)
26. Otsuki M, Fujii M, Nakamura T, et al: Loxiglumide: A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas. Dig Dis Sci 34:857-864, 1989
27. Hashimura E, Shimizu F, Nishino T, et al: Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide by selective suppression of cross reactive antibody response. J Immunol Methods 55:375-387, 1982
28. Kanayama S, Himeno S, Higashimoto Y, et al: Plasma cholecystokinin-octapeptide like immunoreactivity in patients with hepatic cirrhosis. Life Sci 41:1915-1920, 1987
29. Ceska M, Birath K, Brown B: A new and rapid method for the clinical determination of α-amylase activities in human serum and urine. Clin Chim Acta 26:437-444, 1969
30. Bondar RJL, Mead DC: Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chem 20:586-590, 1974
31. Morgan CR, Lazarow AL: Immunoassay of insulin: Two antibody system. Diabetes 12:115-126, 1963
32. Stern DH, Walsh JH: Gastrin release in postprandial ulcer patients: Evidence of release of duodenal gastrin. Gastroenterology 64:363-369, 1973
33. Jorde R, Burhol PG: The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes. Ital J Gastroenterol 19:76-78, 1987
34. Kreymann B, Ghatei MA, Williams G, et al: Glucagon-like peptide 1 7-36: A physiological incretin in man. Lancet 2:1300-1304, 1987
35. Orskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagon-like peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661, 1993
36. Rushakoff RJ, Goldfine ID, Carter JD, et al: Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. J Clin Endocrinol Metab 65:395-401, 1987
37. Reimers J, Nauck M, Creutzfeldt W, et al: Lack of insulino-tropic effect of endogenous and exogenous cholecystokinin in man. Diabetologia 31:271-280, 1988
38. Schmid R, Schusdziarra V, Schulte-Frohlinde E, et al: Effect of CCK on insulin, glucagon, and pancreatic polypeptide levels in humans. Pancreas 4:653-661, 1989
39. Fried M, Schwizer W, Beglinger C, et al: Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecystokinin receptor antagonist loxiglumide. Diabetologia 34:721-726, 1991
40. Meerof JC, Go VLW, Phillips SD: Control of gastric emptying by duodenal contents in man. Gastroenterology 68:1144-1151, 1975
41. Owyang C, May D, Louie DS: Trypsin suppression of pancreatic enzyme secretion. Differential effect on cholecystokinin release and the enterohepatic reflex. Gastroenterology 91:637-643, 1986
42. Hildebrand P, Ensinck JW, Ketterer S, et al: Effect of cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans. J Clin Endocrinol Metab 72:1123-1129, 1991
43. Liddle RA, Gertz BJ, Kanayama S, et al: Regulation of pancreatic endocrine function by cholecystokinin: Studies with MK-329, a nonpeptide cholecystokinin receptor antagonist. J Clin Endocrinol Metab 70:1312-1318, 1990
44. Zawalich WS, Diaz VA: Prior cholecystokinin exposure sensitizes islets of Langerhans to glucose stimulation. Diabetes 36:118-122, 1987
45. Fehmann H-C, Goke R, Goke B, et al: Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. Biochim Biophys Acta 1091:356-363, 1991
46. Nakano I, Funakoshi A, Shinozaki H, et al: High plasma cholecystokinin response following ingestion of test meal by patients with non-insulin dependent diabetes mellitus. Regul Pept 14:229-236, 1986
47. Khalil T, Walker P, Wiener I, et al: Effect of aging on gallbladder contraction and release of cholecystokinin-33 in humans. Surgery 98:423-429, 1985